Stocks in the DAX index appear set for an increase.
Alright, let's dive into the market! Here's a fresh take on the current stock market situation and what investors should keep their eyes on today.
Wondering if the rally on the DAX will continue? Look no further as the German benchmark index has gained 0.7 percent and currently stands at 20,269 points. The positive price signals from the US market and hopes for a more cautious trade policy from incoming US President Donald Trump have contributed to this upward trend.
The Siemens Energy stock has been leading the pack, gaining nearly four percent. This upward trend is no surprise, with Siemens Energy previously hitting an all-time high and pushing the company’s market value to over €66 billion. The company’s leading position in cleantech plays a major role in its impressive performance.
On the flip side, the Bayer stock and Symrise stocks registered the largest declines in the DAX, with a 2.7 percent and 2.8 percent drop respectively.
Bayer, known for its blockbuster medication Xarelto, is currently focusing on new drugs to drive long-term growth. The drug's sales are expected to decline due to patent losses, with stabilization of sales being the initial priority before growth is expected again from 2027.
Over at Symrise, analysts have lowered the price target but maintained the rating at "Hold". The current valuation of the sum of all parts of the aroma company may explain this move, with the earnings estimates remaining largely unchanged.
In case you're curious, Siemens Energy's strong performance could be playing out over the long term, with some analysts predicting that the stock market rally could last until 2025[1]. So, buckle up and keep a close eye on these stocks!
[1] Enrichment Data - 15% and more? The stock market rally could keep going in 2025, but...
Contains material from dpa-AFX
- If you're interested in finance and investing, it's worth monitoring Siemens Energy's stock, as some analysts predict its strong performance could continue until 2025.
- Businesses keeping a keen eye on the market should also be aware of the potential impact on Bayer's stock, as the pharmaceutical giant is focusing on new drugs to drive long-term growth, following patent losses expected to reduce sales until 2027.
